 |
Top 7 Brain cancer treatment startups in USA
Oct 25, 2025 | By Jason Kwon | 28 |
1
Funding: $614.6M
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
2
Funding: $337M
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
3
Funding: $253.7M
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
4
Funding: $95M
Lantern Pharma is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action.
Lantern Pharma is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action.
5
Funding: $65M
Actuate Therapeutics is a biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Our work has led to some fascinating results around anti-tumor activity in the brain, pancreas, lungs, and breasts.
Actuate Therapeutics is a biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Our work has led to some fascinating results around anti-tumor activity in the brain, pancreas, lungs, and breasts.
6
Funding: $3.5M
OX2 Therapeutics is a healthcare therapeutics company that focuses on treating brain tumors.
OX2 Therapeutics is a healthcare therapeutics company that focuses on treating brain tumors.
7
Funding: $625K
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy. The startup’s lead candidate ACXT-3102, enables effective ligand binding to deliver targeted cytotoxic payloads in patients suffering from pancreatic adenocarcinoma. Accuronix also is developing MTDCs for other types of cancers such as breast or brain cancer.
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy. The startup’s lead candidate ACXT-3102, enables effective ligand binding to deliver targeted cytotoxic payloads in patients suffering from pancreatic adenocarcinoma. Accuronix also is developing MTDCs for other types of cancers such as breast or brain cancer.
★
See also:
